Drug Profile
Research programme: siRNA therapeutics - AstraZeneca/Silence Therapeutics
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Silence Therapeutics
- Developer AstraZeneca; Silence Therapeutics
- Class Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Respiratory tract disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Respiratory-tract-disorders in United Kingdom
- 21 Mar 2012 Preclinical development is ongoing
- 21 Apr 2010 Silence Therapeutics and AstraZeneca have extended their collaborative agreement for the development of delivery approaches for siRNA therapeutics